drugset
drugset / Trial / NCT04488575

Safety and Efficacy of EDP1815 in the Treatment of Patients Hospitalized With COVID-19 Infection

NCT04488575 ↗

Phase 2 Terminated 16 enrolled Evelo Biosciences, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

Evelo will investigate the safety and efficacy of EDP1815 in the treatment of patients hospitalized with SARS-CoV-2 Infection

Timeline

Start
2020-08-26
Primary completion
2021-05-16
Completion
2021-05-19

Drugs

EvaluationDrugModalityDoseRoute
Subject EDP1815 Other / unclassified — Oral

Indications

COVID-19